肾细胞癌的靶向治疗现状

The present situation of targeted drug therapy of renal cell carcinoma

随着对肿瘤新生血管生成机制的了解,一系列针对肿瘤血管生成的抗肿瘤分子靶向药物在晚期肾细胞癌的治疗方面取得了长足的进展。与传统的免疫治疗(细胞因子治疗)相比,接受靶向药物治疗患者的无进展生存期和总生存期都获得显著提高。靶向药物引起的毒副反应特点与传统化疗药物有所不同,但均处于可接受程度。由于靶向药物在治疗晚期肾癌方面取得的良好结果,新的治疗领域研究正在进行中,如高危局限性肾癌根治性肾切除术后的辅助治疗。应用足够剂量、维持治疗和正确处理毒副反应是获得临床疗效的三个基本条件。

With the understanding of tumor angiogenesis,considerable progress has been made in the treatment of patients with metastatic renal cell carcinoma,treated with a serial of targeted anti-tumor drugs.Comparing with traditional immunotherapies,such as cytokine therapy,targeted drug therapy significantly prolonged both the progression free survival and overall survival of the patients.The side-effects induced by targeted drugs are acceptable,although they are some different from which of the traditional chemotherapy drugs.Because of the excellent results of targeted drugs in the treatment of metastatic renal cell carcinoma,new studies of treatment option are being investigated,such as adjuvant therapy with targeted drugs in the patients of local advanced renal cancer.Sufficient treatment dosage,continued treatment cycle and best side-effects managements are very important for achieving better clinical effects.